Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

H. pylori, a gram-negative bacillus, thrives in the stomach's acidic environment and impairs somatostatin production. This disruption increases gastrin and acid secretion while reducing bicarbonate production, compromising the stomach's defensive barrier and leading to gastric and duodenal ulcers. The resulting imbalance leaves the mucosa vulnerable to ulcer formation.

H. pylori detection employs endoscopic biopsy, which provides direct evidence of the bacterium's presence in the stomach lining. Noninvasive alternatives include serology, fecal antigen tests, and urea breath tests, offering less invasive diagnostic options for patients requiring confirmation of infection before treatment begins.

Triple therapy combines two antibiotics—clarithromycin and metronidazole or amoxicillin—with acid suppressive drugs for peptic ulcer disease proton pump inhibitors. Quadruple therapy adds bismuth subsalicylate to the regimen, broadening the antibiotic spectrum with metronidazole and tetracycline to enhance eradication success rates and overcome resistance.

Bismuth subsalicylate and bismuth-containing preparations like bismuth chelate enhance mucosal protection by bolstering the stomach's defensive barrier against acid damage. These cytoprotective agents directly inhibit H. pylori activity, making them valuable components of quadruple therapy regimens designed to maximize bacterial eradication and treatment success.

Effective H. pylori treatment regimens typically last 10 to 14 days, as shorter treatment durations prove less effective at achieving complete bacterial eradication. Maintaining the full course of therapy is essential for successful infection clearance and reducing the risk of treatment failure or recurrent infection.

H. pylori treatment faces several obstacles, including medication-related side effects such as nausea, vomiting, and blackening of the tongue and feces. The inconvenience of multiple-drug regimens reduces patient compliance, and antibiotic resistance to clarithromycin and metronidazole can lead to eradication failure despite appropriate therapy.

The proton pump inhibitor curtails excessive acid production in the stomach, creating a less hostile environment for antibiotic action against H. pylori. By reducing acid secretion, the PPI supports antibiotic efficacy while protecting the gastric mucosa during treatment and promoting healing of existing ulcers.